Francis Medical, a Minnesota-based medical technology company, has unveiled a groundbreaking device designed to treat prostate cancer using high-temperature water vapor.
The new system, known as Vanquish, offers a non-invasive solution that could reshape the future of cancer therapy.
The Vanquish device delivers precise, targeted heat through a thin probe inserted via the urethra.
A specialized needle then directs 100°C water vapor directly into the tumor site. This process, which takes just 10 seconds, destroys cancerous cells while preserving surrounding healthy tissue. Ultrasound imaging is used throughout the procedure to ensure accuracy and safety.
Recognizing the potential of this new method, the US Food and Drug Administration (FDA) granted Vanquish a special breakthrough device designation in 2023. This status accelerates the regulatory process for promising technologies in cancer care.
Preliminary clinical trials were conducted on 15 patients diagnosed with localized prostate cancer. The device demonstrated a 100% success rate with no serious side effects reported. Encouraged by these results, Francis Medical plans to expand clinical trials to include 235 patients across 26 medical centers in the US.
Medical experts highlight several key advantages of the Vanquish technology:
- Reduced impact on healthy prostate tissue
- Lower risk of damage to surrounding organs
- Preservation of prostate functionality
- Minimized risk of sexual health complications
Follow the latest news on Google News
